Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ENVB 
Enveric Biosciences Inc (ENVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ENVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -71.07% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.50M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 5400929 | Beta 0.08 | 52 Weeks Range 1.13 - 15.75 | Updated Date 03/30/2025 |
52 Weeks Range 1.13 - 15.75 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -34.31 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.88% | Return on Equity (TTM) -308.64% |
Valuation
Trailing PE - | Forward PE 23.09 | Enterprise Value -4419562 | Price to Sales(TTM) 0.08 |
Enterprise Value -4419562 | Price to Sales(TTM) 0.08 | ||
Enterprise Value to Revenue 1.76 | Enterprise Value to EBITDA 0.29 | Shares Outstanding 1921910 | Shares Floating 656524 |
Shares Outstanding 1921910 | Shares Floating 656524 | ||
Percent Insiders 0.07 | Percent Institutions 7.16 |
Analyst Ratings
Rating 4 | Target Price 8.5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enveric Biosciences Inc
Company Overview
History and Background
Enveric Biosciences, Inc. (formerly Aevi Genomic Medicine, Inc.), founded in 2006, is a biotechnology company focused on developing novel cannabinoid medicines for cancer supportive care. The company has evolved to focus on developing small molecule therapeutics for oncology.
Core Business Areas
- EVM201 (Psybrin Program): A synthetic prodrug of psilocin being developed for the treatment of cancer-related distress. It is designed to minimize the psychedelic effect while retaining potential therapeutic benefits.
- EVM301 (Novel New Chemical Entity Program): A cannabinoid analog targeting difficult-to-treat cancers. It is designed to directly target and inhibit cancer cell growth.
- Discovery Program: Research and development efforts focused on identifying and developing novel cannabinoid-based therapeutics.
Leadership and Structure
The leadership team includes Joseph Batholomeo (President and CEO), Dr. Bob Dagher (Chief Medical Officer) and members of the board. The organizational structure is typical of a biotechnology company with research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- EVM201: A synthetic prodrug of psilocin aiming to treat cancer-related distress by improving the control of side-effects. The competitors for this product include COMPASS Pathways, Cybin, and MindMed. Market share data is currently unavailable as the product is in clinical development.
- EVM301: A novel cannabinoid analog targeting difficult-to-treat cancers. It has a potential for direct anticancer activity. Competitors include companies developing cancer therapeutics such as large pharma and other biotech firms. Market share data is currently unavailable as the product is in early clinical development.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investment in cancer and neurological disorder therapeutics. There is increased interest in cannabinoid and psychedelic based medicines.
Positioning
Enveric Biosciences is positioned as a developer of novel cannabinoid medicines, focused on cancer supportive care and oncology. Its competitive advantage lies in its proprietary cannabinoid and prodrug platform technologies.
Total Addressable Market (TAM)
The total addressable market for cancer supportive care and cancer therapeutics is estimated to be billions of dollars. Enveric's positioning allows it to target specific unmet needs within this large market, focusing on cancer-related distress and difficult-to-treat cancers. Market size is estimated at $200B globally by 2030. Enveric has not captured a large percentage of this to date.
Upturn SWOT Analysis
Strengths
- Proprietary cannabinoid and prodrug platform technologies
- Focus on unmet needs in cancer supportive care and oncology
- Experienced leadership team
- Novel product candidates
Weaknesses
- Early-stage clinical development
- Limited financial resources
- High attrition rate in drug development
- Dependence on successful clinical trial outcomes
Opportunities
- Growing market for cancer supportive care and therapeutics
- Increasing acceptance of cannabinoid-based medicines
- Potential for partnerships and collaborations
- Expansion into new therapeutic areas
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Changes in patent laws
- Economic downturn and funding constraints
Competitors and Market Share
Key Competitors
- GWPH
- CRBP
- ZYNE
- CBBT
Competitive Landscape
Enveric Biosciences faces intense competition from larger, better-funded pharmaceutical companies. Its advantages lie in its niche focus and proprietary technology.
Major Acquisitions
NeuroTherapeutics, Inc.
- Year: 2021
- Acquisition Price (USD millions): 5
- Strategic Rationale: Expanded pipeline of cannabinoid-based therapeutics and intellectual property.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on early-stage drug development.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates. Analyst projections are not available.
Recent Initiatives: Recent initiatives include advancing EVM201 and EVM301 through clinical trials, exploring partnerships, and strengthening the intellectual property portfolio.
Summary
Enveric Biosciences is an early-stage biotech company focused on developing cannabinoid-based therapies, with its focus on cancer treatment. The company is dependent on the success of its clinical trials. The company has limited financial resources, it must capitalize on partnerships. Success depends on clinical trial outcomes and competitive landscape.
Similar Companies
- GWPH
- CRBP
- ZYNE
- CBBT
- TLRY
- CGC
Sources and Disclaimers
Data Sources:
- Enveric Biosciences' website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enveric Biosciences Inc
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2015-06-24 | CEO & Director Dr. Joseph Edward Tucker Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.enveric.com |
Full time employees 7 | Website https://www.enveric.com | ||
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.